Literature DB >> 15012620

Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours.

Sabina Zacharieva1, Iliana Atanassova, Maria Orbetzova, Emil Nachev, Krassimir Kalinov, Georgy Kirilov, Rositza Shigarminova, Radina Ivanova, Georgy Dashev.   

Abstract

OBJECTIVES: The aim of the present study was to determine vascular endothelial growth factor (VEGF), prostaglandin E(2) (PGE(2)) and active renin levels in patients with hormonally active adrenal tumours.
DESIGN: The study was comprised of 16 patients with primary aldosteronism, 13 patients with active Cushing's syndrome due to adrenal adenomas, 8 patients with adrenal carcinomas, 19 patients with phaeochromocytoma and 19 healthy volunteers.
METHODS: Active renin in plasma was determined by a two-site immunoradiometric assay. VEGF in sera samples and PGE(2) in 24-h urine were measured by ELISA.
RESULTS: VEGF was significantly elevated in all the four groups of patients as compared with the controls. VEGF levels in patients with Cushing's syndrome were higher than those in patients with primary aldosteronism. Patients with adrenal carcinomas had the highest VEGF levels and the differences reached significance as compared with patients with primary aldosteronism and phaeochromocytoma. PGE(2) levels were not significantly different among groups. Active renin was significantly the lowest in patients with primary aldosteronism and significantly the highest in patients with phaeochromocytoma compared with the controls. Active renin in patients with primary aldosteronism was significantly lower than in those with Cushing's syndrome, phaeochromocytoma and adrenal carcinoma.
CONCLUSIONS: Our data indicated that the mean level of VEGF in patients with all investigated adrenal tumours was significantly higher than in healthy controls. The cortisol-producing tumours appear to have increased angiogenic potential. Angiogenesis is probably associated not only with malignancy but also with functional activity of the adrenal tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15012620     DOI: 10.1530/eje.0.1500345

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.

Authors:  Yun-Ze Xu; Yu Zhu; Zhou-Jun Shen; Jia-Yan Sheng; Hong-Chao He; Gui Ma; Yi-Cheng Qi; Ju-Ping Zhao; Yu-Xuan Wu; Wen-Bin Rui; Qing Wei; Wen-Long Zhou; Xin Xie; Guang Ning
Journal:  Endocrine       Date:  2011-06-25       Impact factor: 3.633

Review 2.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

3.  An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma.

Authors:  Megumi Nakamura; Yasuhiro Miki; Jun-Ichi Akahira; Ryo Morimoto; Fumitoshi Satoh; Shigeto Ishidoya; Yoichi Arai; Takashi Suzuki; Yutaka Hayashi; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

4.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

5.  A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation causing leukocytosis.

Authors:  Emil Lou; Jeremy Goodwin; David N Howell; John Hicks; L Brett Caram
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

6.  Cushing Syndrome: The Role of MSCs in Wound Healing, Immunosuppression, Comorbidities, and Antioxidant Imbalance.

Authors:  Miriam Caffarini; Tatiana Armeni; Pamela Pellegrino; Laura Cianfruglia; Marianna Martino; Annamaria Offidani; Giovanni Di Benedetto; Giorgio Arnaldi; Anna Campanati; Monia Orciani
Journal:  Front Cell Dev Biol       Date:  2019-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.